EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAIVE ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 6-WEEK, RANDOMIZED, PLACEBO-CONTROLLED STUDY

被引：1
|
作者：
Correll, Christoph [1 ]
Goldman, Robert [2 ]
Tocco, Michael [2 ]
Pikalov, Andrei [2 ]
Hsu, Jay [2 ]
Loebel, Antony [2 ]
机构：
[1] Hofstra North Shore LIJ Sch Med, Zucker Hillside Hosp, Hempstead, NY USA
[2] Sunovion Pharmaceut Inc, Marlborough, MA USA
来源：
SCHIZOPHRENIA BULLETIN | 2019年 / 45卷
关键词：
D O I：
10.1093/schbul/sbz018.518
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
F106
引用
收藏
页码：S293 / S294
页数：2
相关论文
共 50 条
  • [31] The efficacy of lurasidone on PANSS subscales in adolescent patients with schizophrenia: Results from a 6-week, double-blind, placebo-controlled, multicenter study
    Correll, C.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2017, 41 : S90 - S91
  • [32] Efficacy and Safety of Quetiapine in Adolescents with Schizophrenia Investigated in a 6-Week, Double-Blind, Placebo-Controlled Trial
    Findling, Robert L.
    McKenna, Kathleen
    Earley, Willie R.
    Stankowski, Jill
    Pathak, Sanjeev
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2012, 22 (05) : 327 - 342
  • [33] Lurasidone monotherapy in the treatment of bipolar I depression: Efficacy Results of a randomized, double-blind, placebo-controlled, 6-week elevate study
    Kato, T.
    Ishigooka, J.
    Masuda, T.
    Watabe, K.
    Fujimori, T.
    Higuchi, T.
    BIPOLAR DISORDERS, 2019, 21 : 131 - 131
  • [34] Atomoxetine in the treatment of psychostimulant-naive children and adolescents with ADHD: a 6-week, randomized, placebo-controlled trial in Russia
    Martenyi, F.
    Zavadenko, N.
    Jarkova, N.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S527 - S528
  • [35] Efficacy and Safety of Lurasidone in a Younger Population With Bipolar Depression: Pooled Post-hoc Analysis of Two Placebo-controlled Studies
    Davey, Chris
    Ratheesh, Aswin
    Tocco, Michael
    Mao, Yongcai
    George, David
    Pikalov, Andrei
    Singh, Manpreet K.
    CNS SPECTRUMS, 2023, 28 (02) : 249 - 249
  • [36] The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials
    Kato, Masaki
    Masuda, Takahiro
    Sano, Fumiya
    Kato, Tadafumi
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 337 : 150 - 158
  • [37] Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naive versus previously treated adolescents with an acute exacerbation of schizophrenia
    Correll, Christoph U.
    Tocco, Michael
    Hsu, Jay
    Goldman, Robert
    Pikalov, Andrei
    EUROPEAN PSYCHIATRY, 2022, 65 (01)
  • [38] Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study
    Ishigooka, Jun
    Iwashita, Shuichi
    Tadori, Yoshihiro
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2018, 72 (09) : 692 - 700
  • [39] Recovery in bipolar depression: analysis of a 6-week, placebo-controlled lurasidone trial followed by a 6-month continuation study
    Siu, C.
    Loebel, A.
    Rajagopalan, K.
    Pikalov, A.
    Cucchiaro, J.
    Ketter, T.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S492 - S492
  • [40] Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial
    Correll, Christoph U.
    Skuban, Aleksandar
    Ouyang, John
    Hobart, Mary
    Pfister, Stephanie
    McQuade, Robert D.
    Nyilas, Margaretta
    Carson, William H.
    Sanchez, Raymond
    Eriksson, Hans
    AMERICAN JOURNAL OF PSYCHIATRY, 2015, 172 (09): : 870 - 880
12345